Masimo Sphb News Today

Masimo NASDAQ MASI today announced the CE mark under the European Union Medical Device Regulation for the LiDCO boardincable BIC module.

Masimo (Nasdaq:MASI) today announced positive data from a study of its hemoglobin monitoring for patients undergoing cesarean section.

30.11.2022 - Masimo (NASDAQ: MASI) today announced the findings of a prospective, double-blinded, randomized, controlled trial published in the Journal of the College of Physicians and Surgeons Pakistan. In the study, Dr. Sukriye Akdag and colleagues at Marmara ... Seite 1

Press release content from Business Wire. The AP news staff was not involved in its creation.

New Study Associates Masimo SpHb, Noninvasive and Continuous Hemoglobin Monitoring, as Part of Pediatric Patient Blood Management, with Reduced ICU Stays and Postoperative Transfusion 55.43 hours 25.34 hours (48 hours median) 33.48 hours 12.25 hours (24 hours median) 0.001 179.02 mL 163.06 mL (145 mL) 102.69 mL 73.87 mL (105 mL) 0.033 71.96 mL 94.95 mL (25 mL) 28.15 mL 64.35 mL (0 mL) 0.043 462.59 mL 158.91 mL (500 mL) 0.048 270,821 74,474 1.47 mmol/L 0.64 mmol/L (1.25 mmol/L) 1.18 mmol/L 0.63 ...

Masimo New Study Associates Masimo SpHb®, Noninvasive and Continuous Hemoglobin Monitoring, as Part of Pediatric Patient Blood Management, with Reduced ICU Stays and Postoperative Transfusion Thursday, December 10, 2020 2:34PM IST (9:04AM GMT)   Masimo (NASDAQ: MASI) announced today the findings of an abstract recently presented at Euroanaesthesia 2020 in which Dr. Saraçoğlu and colleagues at Marmara University in Istanbul, Turkey investigated the efficacy of Masimo noninvasive and continu...